anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a traditional Chinese medicine composition for treating perianal abscess at an early postoperative stage, which is prepared from the following raw material medicines in parts by weight: 10-15 parts of platycodon grandiflorum, 6-9 parts of liquorice, 10-15 parts of immature bitter orange, 10-15 parts of Chinese herbaceous peony, 3-6 parts of ginger, 12-15 parts of Chinese date, 15-20 parts of Chinese waxgourd seed, 24-30 parts of coix seed, 6-9 parts of rhubarb, 10-15 parts of golden cypress, 10-15 parts of giant knotweed and 10-15 parts of corydalis tuber. The invention also comprises a preparation method of the traditional Chinese medicine composition and application of the traditional Chinese medicine composition in preparation of a medicine for treating the perianal abscess at the initial postoperative stage. Its advantages are: 1. the raw materials are compatible with each other, and supplement each other to achieve synergistic effect. 2. Has the effects of clearing away heat and toxic materials, relieving swelling and expelling pus, can effectively treat perianal abscess, and has good curative effect. 3. The traditional Chinese medicine composition has the advantages of no toxic or side effect, low price, simple and convenient preparation method and high cure rate.
Calcium oxalate kidney stones, the most prevalent type of kidney stones, undergo a multi-step process of crystal nucleation, growth, aggregation, and secondary transition. The secondary transition has been rather overlooked, and thus, the effects on the disease and the underlying mechanism remain unclear. Here, we show, by periodic micro-CT images of human kidney stones in an ex vivo incubation experiment, that the growth of porous aggregates of calcium oxalate dihydrate (COD) crystals triggers the hardening of the kidney stones that causes difficulty in lithotripsy of kidney stone disease in the secondary transition. This hardening was caused by the internal nucleation and growth of precise calcium oxalate monohydrate (COM) crystals from isolated urine in which the calcium oxalate concentrations decreased by the growth of COD in closed grain boundaries of COD aggregate kidney stones. Reducing the calcium oxalate concentrations in urine is regarded as a typical approach for avoiding the recurrence. However, our results revealed that the decrease of the concentrations in closed microenvironments conversely promotes the transition of the COD aggregates into hard COM aggregates. We anticipate that the suppression of the secondary transition has the potential to manage the deterioration of kidney stone disease.
<P>PROBLEM TO BE SOLVED: To provide a new osteogenic agent.  <P>SOLUTION: The bone around a site neighboring a bone tissue can be easily made by sustainedly releasing statin at the site. The osteogenic agent comprises 1. preparing a topically sustainedly releasing preparation from the statin or a derivative thereof, and 2. having the component of a carrier for the topically sustainedly releasing preparation selected from (1) calcium sulfate, (2) calcium phosphate and (3) calcium carbonate. The statin or the derivative thereof is topically administered. The topical administration comprises directly filling the preparation into a bone-deficient site such as a tooth-extracted recess and a cavity of pustule, a fracture site, the surrounding of an artificial implant such as an artificial dental root, and an absorbed alveolar bone site.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
PURPOSE:To obtain the titled composition effective in protecting the skin over a long period without causing sticky feeling and remaining on the skin even after washing the skin with water, by dissolving a specific high-molecular weight silicone in a liquefied gas such as flon(CFC) gas and LPG and using in the form of aerosol. CONSTITUTION:The objective aerosol composition is composed of (A) 2-50wt.% (preferably 2-30wt.%) one or more high-molecular weight silicones of formula (R1 is methyl; a part of R1 may be phenyl; R2 is methyl or OH; n is integer of 3,000-20,000) (e.g. dimethylpolysiloxane or methylphenylpolysiloxane) based on the whole cosmetic and (B) 5-90wt.% flon gas (e.g. flon 11 or flon 21) and/or a liquefied petroleum gas (e.g. propane or isobutane). The composition is easily applicable to the skin to form a uniform thin film of silicone resin. There is little contamination of an object with the composition even by handling the object with a hand coated with the composition.
The invention discloses an anti-haze beverage for reducing organ injuries caused by haze and a preparation method thereof. The anti-haze beverage comprises functional raw materials and a food additive. The functional raw materials comprise 5-15 parts of coix seeds, 10-20 parts of radix stellariae, 15-25 parts of white jasmine flowers, 4-8 parts of herba leonuri, 2-4 parts of tuber fleeceflower stems, 10-20 parts of American ginseng, 10-20 parts of fructus evodiae, 6-10 parts of radix cynanchi panicullati and 2-4 parts of radix clematidis and spina date seeds. The weight ratio of radix clematidis to spina date seeds is (1-3):1. Experiments indicate that the anti-haze beverage can resist organ injury reactions induced by PM2.5 and keep the organ coefficient at a normal level. The functions of the anti-haze beverage are possibly relevant to the weight ratio of radix clematidis to spina date seeds. Compared with the prior art, the anti-haze beverage has prominent substantive distinguishing features and remarkable progress.
MBL is a precursor condition to chronic lymphocytic leukemia (CLL), characterized by monoclonal B-cells in blood. Mosaic chromosomal alterations (mCAs) are a form of clonal hematopoiesis that include gains, losses, and copy-neutral loss-of-heterozygosity of large DNA segments. Both MBL and mCAs have been found to increase the risk of CLL and lymphoid malignancies, and the aim of our study was to investigate how mCAs relate to MBL, which is currently unknown. We analyzed genetic, flow cytometric, and hematologic data from 4632 individuals from the Mayo Clinic Biobank and CLL Database. MBL was detected using flow cytometry and classified as high-count (HC) or low-count (LC) MBL based on clone size. mCAs were detected primarily from whole blood DNA using sensitive SNP-array-based analyses. mCAs commonly altered in CLL (deletion of 6q, 11q, 13q, 17p, and trisomy 12) were specific (>99%) to individuals with MBL and CLL. HC-MBL and LC-MBL individuals were 881-fold and 8-fold, respectively, more likely to harbor CLL-associated mCAs than those without MBL. The cell fraction bearing these mCAs typically exceeded the B-cell fraction, suggesting their origin prior to the B-cell lineage. Integrating genetic and blood count data enabled detecting HC-MBL with high specificity in a biobank sample. These results quantify the contribution of mCAs to MBL and could enable large studies of HC-MBL without the need for flow cytometric screening.
A 3+3 design in adult subjects. Subjects in the first dose level will receive ATLCAR.CD30.CCR4 cells alone, once safety has been established, the initial dose of ATLCAR.CD30.CCR4 will be combined with a fixed dose of ATLCAR.CD30 cells in the next dose level. Every time the dose of ATLCAR.CD30.CCR4 is escalated, subjects in that dose level will receive ATLCAR.CD30.CCR4 alone prior to subsequent dose level enrolling subjects to receive a combination of fixed dose ATLCAR.CD30 and the selected dose level of ATLCAR.CD30.CCR4. The six dose levels will consist of: dose level 1 = 2 × 10\^7 ATLCAR.CD30.CCR4 cells/m2; dose level 2 = 1 × 10\^8 ATLCAR.CD30 cells/m2 and 2 × 10\^7 ATLCAR.CD30.CCR4 cells/m2; dose level 3 = 5 × 10\^7/m2 ATLCAR.CD30.CCR4 cells/m2; dose level 4 = 1 × 10\^8 ATLCAR.CD30 cells/m2 and 5 × 10\^7 ATLCAR.CD30.CCR4 cells/m2; dose level 5 = 1 × 10\^8/m2 ATLCAR.CD30.CCR4 cells/m2; dose level 6 = 1 × 108 ATLCAR.CD30 cells/m2 and 1 × 108 ATLCAR.CD30.CCR4 cells/m2.
Single 6 mL IA injection of Synvisc-One (48 mg of cross-linked hylan polymer) at Day 0 (Initial Treatment). Participants received repeat injection based on physician's discretion of safety and efficacy (no major safety concerns and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) A1 subscore \[measurement of pain while walking on flat surface\] between 40-80 mm, measured on a 0-100 mm scale with 0 represents no pain and 100 represents worst possible pain) at Week 26, 39 or 52 (Repeat treatment).
This group of 12 patients will be given 36Gy of Stereotactic Body Radiotherapy (SBRT) divided into six separate doses. This will be delivered two to three time per week.
1. A composition for human consumption, comprising solid creatine suspended in an edible viscous liquid or semi-liquid supporting matrix. 2. A composition according to claim 1, is which the composition has a pH in the range 2.5 to 6.5. 3. A composition according to claim 1 or 2, in which the composition has a pH in the range 3.0 to 6. 4. A composition according to any one of the preceding claims, comprising one or more additional components selected from the group consisting of: electrolytes, vitamins, lipids, carbohydrates, amino acids, trace elements, colorings, flavours, artificial sweeteners, natural health improving substances, antioxidants, stabilizers, preservatives and buffers. 5. A composition according to any one of the preceding claims, wherein the edible supporting matrix comprises one or more of the following: honey, syrup, molasses, treacle and concentrated Aloe Vera gel, plant-derived or algal-derived polysaccharide, gum, thickening agents, end gelatinous substances, galactomannans, dextrans, guar gum, locust bean gum, xanthan gum, carrageen, carrageenan, traganth gum, acacia gum, tara gum, gellan, gelatine, alginate, agar or pectin. 6. A composition according to any one of the preceding claims, wherein creatine is present in the form of creatine monohydrate or creatine phosphate. 7. A composition according to any one of the preceding claims, wherein a normal serving thereof provides a physiologically effective dose of creatin. 8. A composition according to any one of the preceding claims wherein a normal serving thereof provides 1-10 gms creatine. 9. A method of preparing a creatine containing composition for human consumption in which the creatine is substantially stable, the method comprising the steps of: providing creatine in solid form; and mixing the solid creatine with an edible viscous liquid or semi-liquid supporting matrix so as to distribute the solid creatine within the supporting matrix. 10. A method of storing creatine in stable form, the method composing the steps of: providing creatine in solid form; mixing the solid creatine with an edible viscous liquid or semi-liquid supporting matrix so as to suspend the creatine therein; and storing the suspended creatine at ambient temperature or below.
Part B will investigate EP395 as a 'perpetrator' of DDIs. The impact of EP395 on the PK of a CYP3A4 substrate and a Pgp substrate will be assessed. Midazolam has been selected as the CYP3A4 substrate and digoxin as the Pgp substrate.
The randomized, placebo-controlled, three-arm trial will be conducted to evaluate the efficacy of infrared laser moxibustion (ILM) and sham ILM (SILM) compared to waitlist control (WLC) for moderately to severely fatigued BCS. The two intervention groups will receive real/sham infrared laser moxibustion on four acupoints (e.g. ST36 (bilateral), CV4, and CV6) for 20 minutes each session for six weeks (two times per week). The primary endpoint is the change in fatigue scores from Baseline to Week 6 as measured by the Chinese version of the Brief Fatigue Inventory (BFI-C). Our secondary aims are to compare the severity of comorbidities (e.g. depression, insomnia, and pain) and biological outcomes (e.g. telomere length) among the three groups.
Patients are randomly arranged in 2 groups Group (A):- Palmer's point is the primary entry site. Group (B):- The umbilicus is the primary entry site.
Preterm birth is associated with various brain injuries. The earlier the period of gestation, more is the incidence of brain injuries. Brain injuries are known to be one of the most important factors leading to significant morbidity and mortality in these vulnerable preterm babies.{1} Cranial ultrasound (CUS) examinations have been performed on preterm infants to diagnose various perinatal brain injuries and for the prediction of long term outcomes.{2} Cranial ultrasonography (CUS) is the preferred modality to image the neonatal brain.{3} The advantages of CUS are numerous: it can be performed at the bedside with little disturbance to the infant, it is relatively safe, and can be repeated whenever needed, enabling visualization of ongoing brain maturation and the evolution of lesions.{4,5}
In the robot arm, a physiotherapist with more than 15 years of experience identified the trigger points in the patient, programmed the robot, and applied robot-controlled air pressure massage for 10 minutes. The ADAMO robot applies an air current to the trigger points on the back of the patient, guided by cameras and computer programs (https://adamorobot.com/). Thermotherapy and rehabilitation exercises were also applied.
The Diabetes Self-Management Education and Support (DSMES) + Appetite Self-Regulation (ASE) intervention includes two, 45-60-minute group sessions delivered via telehealth. These sessions will enable participants to relearn their stomach's hunger and fullness signals and monitor their appetite. Participants will also learn strategies for glucose monitoring and carbohydrate management. Monthly booster sessions will be devoted to problem-solving, addressing barriers to emotion management, and self-monitoring type 2 diabetes mellitus symptoms. Participants will also receive weekly lessons with interactive activities delivered via a digital app.
PURPOSE OF REVIEW: The prevalence of IBD in older adults is rapidly growing. Older adults with IBD are underrepresented in research and clinical trials and yet at great risk for adverse events. Therefore, understanding advanced aged associated constructs in older adults can be critical to improving the management of older adults with IBD.
RECENT FINDINGS: In this review, we present recent studies on frailty in IBD. We identify 4 major themes in the literature: studies that describe frailty in patients with IBD, studies that report on consequences of frailty, studies of frailty as a risk stratification modality, and studies of frailty as an exposure and outcome. In reviewing the literature, we discuss the heterogeneity that exists and outline future directions to ensure appropriate applications for frailty in the field of IBD.
The invention relates to a photosensitizer (e.g. methylene blue or riboflavin) for use in a method of treatment of a pathogenic infection (e.g. viral infection, such as SARS-CoV-2). The methods generally involve contacting a pathogen with the photosensitizer, and subjecting the photosensitizer contacted pathogen to a light source. In one embodiment, said method of treatment comprises (i) contacting a pathogen residing in the oral cavity and/or pharynx of a patient in need thereof with the photosensitizer and (ii) subjecting the photosensitizer contacted pathogen to a light source. Other embodiments relate to topical application of the photosensitizer.
N6-methyladenosine (m6A) alteration is an epigenetic regulator widely involved in the tumorigenicity of hepatocellular carcinoma (HCC). The role of YTH N6-methyladenosine RNA binding protein F3 (YTHDF3), an m6A reader in HCC, requires further investigation. Here, we aim to explore the biological properties of YTHDF3 in HCC and its potential mechanisms. The predictive risk model for HCC was developed by analyzing the expression of genes associated with m6A in HCC using online datasets. WB and qPCR were employed to assess YTHDF3 expression in HCC and its correlation with the disease's clinicopathological characteristics. Both in vitro and in vivo methods were utilized to evaluate the biological effects of YTHDF3 in HCC. The potential targets of YTHDF3 were identified and confirmed using RNA-seq, meRIP-seq, and linear amplification and sequencing of cDNA ends (Lace-seq). We confirmed that YTHDF3 is overexpressed in HCC. Patients with higher YTHDF3 expression had a greater risk of cancer recurrence. In both in vitro and in vivo settings, YTHDF3 boosts the migration and invasion capabilities of HCC cells. Through multi-omics research, we identified YTHDF3's downstream target genes as NKD inhibitors of the WNT signaling pathway 1 (NKD1) and the WNT/β-catenin signaling pathway. With m6A modification, YTHDF3 suppresses the transcription and translation of NKD1. Additionally, NKD1 inhibited tumor growth by blocking the WNT/β-catenin signaling pathway. The investigation found that the oncogene YTHDF3 stimulates the WNT/β-catenin signaling pathway by m6A-dependently suppressing NKD1 expression in HCC cells. Our findings suggest that YTHDF3 regulates hepatocarcinogenesis, providing fresh perspectives on potential biomarkers and therapeutic targets for HCC.
Deaths from AIDS have declined dramatically since the introduction of highly active antiretroviral therapy in HIV infected patients. However the incidence of heart disease has increased four-fold and is now one of the major causes of death in HIV infected patients. While HIV drugs are known to adversely affect serum lipids, the evidence concerning the association between raised blood pressure (a major risk for cardiovascular disease) HIV and/or its treatment is limited and conflicting. The researchers believe it of interest to study heart disease risk factors in patients with HIV infection to avoid one premature cause of death (AIDS) being replaced with another potentially preventable cause of death and disability (heart disease). In this cross sectional observational study the researchers will systematically measure blood pressure and other cardiovascular risk factors in HIV positive patients on and off antiretroviral therapy. These individuals will be matched for age, sex and ethnic group with HIV negative individuals.
Parkinson's disease (PD) is a prevalent and intricate neurological condition resulting from a combination of several factors, such as genetics, environment, and the natural process of aging. Degeneration of neurons in the substantia nigra pars compacta (SN) can cause motor and non-motor impairments in patients with PD. In PD's etiology, inflammation and mitochondrial dysfunction play significant roles in the disease's development. Studies of individuals with PD have revealed increased inflammation in various brain areas. Furthermore, mitochondrial dysfunction is an essential part of PD pathophysiology. Defects in the components of the mitochondrial nucleus, its membrane or internal signaling pathways, mitochondrial homeostasis, and morphological alterations in peripheral cells have been extensively documented in PD patients. According to these studies, neuroinflammation and mitochondrial dysfunction are closely connected as pathogenic conditions in neurodegenerative diseases like PD. Given the mitochondria's role in cellular homeostasis maintenance in response to membrane structural flaws or mutations in mitochondrial DNA, their dynamic nature may present therapeutic prospects in this area. Recent research investigates mitochondrial transplantation as a potential treatment for Parkinson's disease in damaged neurons. This review delves into the impact of inflammation and mitochondrial dysfunction on PD occurrence, treatment approaches, and the latest developments in mitochondrial transplantation, highlighting the potential consequences of these discoveries.
Hearing loss is a pivotal risk factor for dementia. It has recently emerged that a disruption in the intercommunication between the cochlea and brain is a key process in the initiation and progression of this disease. However, whether the cochlear properties can be influenced by pathological signals associated with dementia remains unclear. In this study, using a mouse model of Alzheimer's disease (AD), we investigated the impacts of the AD-like amyloid β (Aβ) pathology in the brain on the cochlea. Despite little detectable change in the age-related shift of the hearing threshold, we observed quantitative and qualitative alterations in the protein profile in perilymph, an extracellular fluid that fills the path of sound waves in the cochlea. Our findings highlight the potential contribution of Aβ pathology in the brain to the disturbance of cochlear homeostasis.
BACKGROUND: The association between metabolic syndrome (MetS) and chronic obstructive pulmonary disease (COPD) has not been studied well, particularly in young individuals. We investigated the risk of COPD development in young individuals based on MetS and its components.
METHODS: We used the Korean National Health Information Database to identify 6,891,400 individuals aged 20-39 years who participated in the national health check-up service between 2009 and 2012. Then, we identified individuals with MetS and investigated COPD development based on health insurance claims. Cox proportional hazard regression models were used to calculate the adjusted hazard ratio (aHR) for the risk of COPD development.
RESULTS: During a mean follow-up period of 8.35 years, 13,784 individuals were newly diagnosed with COPD. MetS was associated with an increased risk of COPD (aHR, 1.18; 95% confidence interval [CI], 1.11-1.24). Among the MetS components, except for hyperglycemia, abdominal obesity (aHR, 1.27; 95% CI, 1.19-1.34), hypertension (aHR, 1.05; 95% CI, 1.01-1.10), hypertriglyceridemia (aHR, 1.11; 95% CI, 1.07-1.16), and low high-density lipoprotein cholesterol levels (aHR, 1.16; 95% CI, 1.11-1.22) were significantly associated with COPD development. A higher number of MetS components correlated with an increased risk of COPD development, with the highest risk observed when all five MetS components were present (aHR, 1.55; 95% CI, 1.28-1.87).
CONCLUSION: MetS was associated with COPD development in young individuals. The risk of COPD development increased along with the increasing number of MetS components. These findings suggest that careful monitoring for COPD development is necessary in young individuals with MetS, especially those with multiple components of MetS.
There is disclosed a method of combining mesenchymal stem cells (MSCs) with a bone substrate. In an embodiment, the method includes obtaining tissue having MSCs together with unwanted cells. The tissue is digested to form a cell suspension having MSCs and unwanted cells. The cell suspension is added to the substrate. The substrate is cultured to allow the MSCs to adhere. The substrate is rinsed to remove unwanted cells. In various embodiments, the tissue is adipose issue, muscle tissue, or bone marrow tissue. In an embodiment, there is disclosed an allograft product including a combination of MSCs with a bone substrate in which the combination is manufactured by culturing MSCs disposed on the substrate for a period of time to allow the MSCs to adhere to the substrate, and then rinsing the substrate to remove unwanted cells from the substrate. Other embodiments are also disclosed.